Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26612321 | 0.81 | FDPS (0.43) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL5724408 | 0.81 | FDPS (0.43) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL6530814 | 0.74 | FDPS (0.38) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL27773228 | 0.73 | FDPS (0.37) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| Water SCHEMBL316719 | 0.72 | FDPS (0.41) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL28340215 | 0.71 | FDPS (0.44) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL6690696 | 0.70 | FDPS (0.48) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL29108608 | 0.70 | FDPS (0.35) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL7787139 | 0.69 | FDPS (0.42) | FDPSHDAC1HDAC6LTA4HALDH1A1 | |
| SCHEMBL840562 | 0.69 | FDPS (0.46) | FDPSHDAC1HDAC6LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828241-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | MATEON THERAPEUTICS INC (US) | 2018-09-12 | — | — | EP | disclosed |
| US-9873668-B2 | Compositions and methods for inhibition of cathepsins | MATEON THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| CN-106543179-A | The synthetic method of 4 hydroxyl of medical body, 3 methyl mercapto purine, 5 nitrile | 无锡乾浩生物医药有限公司 | 2017-03-29 | — | — | CN | disclosed |
| CN-106496228-A | The synthetic method of 2,5 dichloro of medical material, 6 ethyl, 5 purine formonitrile HCN | 无锡乾浩生物医药有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106496228-A | The synthetic method of 2,5 dichloro of medical material, 6 ethyl, 5 purine formonitrile HCN | 无锡乾浩生物医药有限公司 | 2017-03-15 | — | — | CN | disclosed |
| US-20160368869-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | BAYLOR UNIVERSITY | 2016-12-22 | — | — | US | disclosed |
| US-9458103-B2 | Compositions and methods for inhibition of cathepsins | MATEON THERAPEUTICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150031915-A1 | Compositions and Methods for Inhibition of Cathepsins | MATEON THERAPEUTICS, INC. | 2015-01-29 | — | — | US | disclosed |
| EP-2828241-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | Oxigene, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8877967-B2 | Compositions and methods for inhibition of cathepsins | OXIGENE, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130296605-A1 | Compositions and Methods for Inhibition of Cathepsins | MATEON THERAPEUTICS, INC. | 2013-11-07 | — | — | US | disclosed |
| WO-2013142038-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | OXIGENE, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2010059418-A1 | SUBSTITUTED TRIAZINE AND PURINE COMPOUNDS, METHODS OF INHIBITING CRUZAIN AND RHODESAIN AND METHODS OF TREATING CHAGAS DISEASE AND AFRICAN TRYPANOSOMIASIS | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (US) | 2010-05-27 | — | — | WO | disclosed |
| US-7381714-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1883646-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-02-06 | — | — | EP | disclosed |
| US-20060276428-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006125190-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031915-A1 | Compositions and Methods for Inhibition of Cathepsins | CTSF, CTSS, CTSZ | FDPS 2642/4885HDAC1 352/4885HDAC6 179/4885 |
| US-20130296605-A1 | Compositions and Methods for Inhibition of Cathepsins | CTSF, CTSS, CTSZ | FDPS 2642/4885HDAC1 352/4885HDAC6 179/4885 |
| US-20060276428-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | FDPS 1487/4885HDAC1 4064/4885HDAC6 4797/4885 |
| US-20160368869-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | CTSF, CTSS, CTSZ | FDPS 2642/4885HDAC1 352/4885HDAC6 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.